LIGAND PHARMA
LIGAND PHARMA operates in Diversified Metals & Mining.
LIGAND PHARMA (LGDN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.043x
Based on the latest financial reports, LIGAND PHARMA (LGDN) has a cash flow conversion efficiency ratio of 0.043x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€36.53 Million) by net assets (€841.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LIGAND PHARMA - Cash Flow Conversion Efficiency Trend (2016–2023)
This chart illustrates how LIGAND PHARMA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
LIGAND PHARMA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LIGAND PHARMA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SILICON LABORATOR
MU:LA5
|
0.029x |
|
Yari Minerals Ltd
AU:YAR
|
0.000x |
|
Parent Capital Corp
V:PAR-H
|
-1.248x |
|
POWER REIT DL-001
F:P8P
|
N/A |
|
Southern Empire Resources Corp
PINK:SMPEF
|
0.099x |
|
Maquia Capital Acquisition Corp
NASDAQ:MAQC
|
0.008x |
|
El-Mor Electric Installation & Services 1986 Ltd
TA:ELMR
|
0.136x |
|
Evolution Energy Minerals Ltd
AU:EV1
|
-0.133x |
Annual Cash Flow Conversion Efficiency for LIGAND PHARMA (2016–2023)
The table below shows the annual cash flow conversion efficiency of LIGAND PHARMA from 2016 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €700.91 Million | €49.58 Million | 0.071x | -69.34% |
| 2022-12-31 | €597.49 Million | €137.85 Million | 0.231x | +140.43% |
| 2021-12-31 | €821.16 Million | €78.80 Million | 0.096x | +24.73% |
| 2020-12-31 | €709.52 Million | €54.59 Million | 0.077x | +301.21% |
| 2019-12-31 | €767.23 Million | €-29.34 Million | -0.038x | -111.05% |
| 2018-12-31 | €560.91 Million | €194.06 Million | 0.346x | +47.82% |
| 2017-12-31 | €399.79 Million | €93.57 Million | 0.234x | +26.79% |
| 2016-12-31 | €341.29 Million | €63.00 Million | 0.185x | -- |